N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS
申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1594857A2
公开(公告)日:2005-11-16
US7208491B2
申请人:——
公开号:US7208491B2
公开(公告)日:2007-04-24
[EN] NOVEL N-MONOACYLATED O-PHENYLENEDIAMINES, THEIR CONDENSED HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS<br/>[FR] NOUVELLES O-PHENYLENEDIAMINES N-MONOACYLEES ET LEURS DERIVES HETEROCYCLIQUES CONDENSES, ET UTILISATION DE CEUX-CI COMME AGENTS PHARMACEUTIQUES
申请人:HOFFMANN LA ROCHE
公开号:WO2004069133A2
公开(公告)日:2004-08-19
Objects of the present invention are new mono-acylated o-phenylendiamines derivatives of formula (I), wherein X represents N, S or O; R represents CH3-(O-CH2CH2)n- or C1-C6-alkyl, which alkyl group is monosubstituted with -CO2H, -OH, R1R2N-, pyridin-2-yl, pyrrolidin-1-yl, piperidino or morpholino; R1, R2 independently from each other denote C1-C6 alkyl; n is 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof. The present invention also encompasses pharmaceutically acceptable salts or prodrugs of the compounds of formula I as well as the use of these compounds to produce medicaments.
N-monoacylated o-phenylenediamines
申请人:——
公开号:US20040157841A1
公开(公告)日:2004-08-12
Mono-acylated o-phenylendiamines derivatives of formula I
1
wherein X and R are as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.